Researchers at Mayo Clinic Cancer Center found that tipifarnib can stall or reverse disease progression for patients with relapsed aggressive non-Hodgkin lymphoma. The study showed a partial response in 18% of patients and stable disease in 21%, while also improving quality of life.
The study found that AVN944 significantly inhibited the IMPDH enzyme and induced biomarkers associated with cancer cell death. The gene HspA1A marker was elevated even at low doses of the drug, indicating potential for tumor cell apoptosis.
A study presented at the American Society of Hematology Meeting shows Revlimid can provide long-term durable results in MDS patients, helping them achieve blood transfusion independence. After over two years of follow-up, two-thirds of patients were completely freed from the need for blood transfusions.
A University of Minnesota study found that over 90% of children and young adults who survive five years or longer after diagnosis and treatment for acute myeloid leukemia (AML) are alive 20 years later. Regular health check-ups and monitoring are crucial to prevent late effects of cancer treatment.
A novel regimen of three chemotherapy drugs resulted in a significant clinical response in patients with previously untreated chronic lymphocytic leukemia (CLL). The treatment showed promise for high-risk patients, with no age restrictions, and minimal side effects.
Scientists have identified nine new genetic mutations in cancer cells that make patients more likely to respond to bortezomib, a common multiple myeloma treatment. These findings may help physicians tailor treatment to individual patients, increasing the effectiveness of the drug.
In a Phase III study, eculizumab provided clinically and statistically significant improvements in intravascular hemolysis, anemia, fatigue and quality of life in patients with paroxysmal nocturnal hemoglobinuria. Eculizumab therapy also reduced adverse events and showed significant benefits in patient-reported outcomes.
Abstracts on Soliris (eculizumab) will be presented at the ASH Annual Meeting, highlighting its potential to reduce thrombosis in paroxysmal nocturnal hemoglobinuria (PNH) patients. The therapy has shown promise in clinical trials with significant reductions in anemia and intravascular hemolysis.
Studies presented at the 2006 Annual Meeting of the American Society of Hematology demonstrate significant gains in treating multiple myeloma and related blood cancers. New treatment regimens, including THALOMID, VELCADE, and REVLIMID, show promising results in both newly diagnosed and relapsed patients.
Researchers at Emory University's Winship Cancer Institute have identified a novel biomarker called 'soluble attractin' that is elevated in patients with malignant astrocytomas. This protein plays a key role in the migration and recurrence of brain tumors, making it a promising target for future therapeutic intervention.
Researchers explored a new approach to maintenance therapy in patients with multiple myeloma, using pamidronate alone or in combination with thalidomide. The study found that ongoing treatment significantly improved cancer-free survival and overall survival probability compared to standard care.
Researchers have discovered three new subtypes of non-small-cell lung cancer tumors based on genetic patterns, which correlate with clinical outcomes such as survival rates and metastatic patterns. This finding may lead to more personalized treatment approaches for patients.
A pioneering study has found that the tumor suppressor gene p53 plays a crucial role in regulating communication between tumor cells and their surrounding stroma. The study identified 111 secreted proteins, 39 of which were enhanced and 21 inhibited by wt-p53 expression.
Researchers at Virginia Commonwealth University identified a new mechanism of action for FTY720, an immunosuppressant drug that also inhibits the activity of key enzyme cPLA2, driving inflammatory disorders. The inhibition may shut down the entire inflammatory pathway without side effects.
Researchers identify crucial role of RhoH GTPase in development and activation of white blood cells, suggesting potential target for leukemia treatment. The study's findings may provide a novel approach to treating hematological malignancy.
Two new blood tests, T-SPOT.TB and QuantiFERON-TB Gold, have improved the detection of latent tuberculosis (TB) infection. These tests offer more accurate results, faster turnaround times, and no return visits compared to traditional tuberculin skin tests.
A study found that cyclin D1 gene overexpression is associated with better survival outcomes and increased sensitivity to the cancer-fighting drug bortezomib in breast cancer patients. This is because it suppresses the activity of another gene, STAT3, which promotes cell growth and prevents tumor cells from dying.
A new study by UCLA researchers analyzed clots removed from the brain blood vessels of 25 stroke victims, revealing that they are composed of similar components. The analysis showed that red blood-cell accumulations often accumulated on clots after impaction in the brain artery, contradicting previous assumptions.
Researchers are investigating antioxidants for preventing or treating rickettsia bacteria, a deadly tick-borne illness. The study, funded by the National Institute of Allergy and Infectious Disease, aims to identify novel therapeutic targets for rickettsial diseases.
Dr. E. Richard Stanley has been recognized with the 2006 E. Donnall Thomas Prize for his groundbreaking research on CSF-1, which plays a crucial role in regulating cell proliferation, differentiation, and function in various diseases. His studies have also shed light on the roles of CSF-1 and its receptor in development and cancer.
Researchers at St. Jude Children's Research Hospital developed a mouse model that explains why gene therapy treatment caused leukemia in some severe immune deficiency patients with XSCID. The study found that the disease itself makes mice susceptible to cancer caused by gene therapy, offering hope for safe treatment.
University of Illinois researchers found unexpected two-way communication between blood stem cells and T cells, changing their fate. This loop may lead to a strong immune response, increasing the risk of graft-versus-host disease or rejection.
Researchers at the University of Pennsylvania School of Medicine used molecular imaging techniques to discover small molecule compounds that can restore normal p53 function in cancer cells, killing human tumor cells. The findings emphasize the growing role of imaging technology in individualized cancer treatments.
Researchers are testing a new drug combination that targets male-specific hormone levels to slow the progression of male breast cancer. The treatment, which involves anastrozole and goserelin, aims to lower overall estrogen levels in men, limiting breast tumor growth.
A novel gene therapy could provide a permanent genetic cure for hemophilia A patients, including those with expensive and ineffective treatments. The treatment involves cloaking Factor VIII in platelets to avoid antibody attacks, making it effective even in patients with inhibitory antibodies.
Researchers found Sprycel to be extremely effective in combating Gleevec resistance, with a major cytogenetic response reported in 45% of chronic phase patients. The drug works by binding to mutant proteins and inhibiting tyrosine kinases, offering CML patients a new treatment option.
Researchers at UC Davis have identified a peptide that targets malignant lymphocytes, distinguishing it from healthy ones. The peptide, LLP2A, has the potential to be used as an imaging agent for patients with lymphoid cancers, offering a more targeted approach than existing monoclonal antibodies.
The St. Jude program in Brazil reduced abandonment rates from 16% to 0.6% and increased event-free survival from 32% to 63%, providing continuous care and psychosocial support to families. The program's success is a model for reducing disparities in cure rates between high- and low-income countries.
Researchers found that a new 'disease control rate' measure was associated with survival, suggesting it could enhance efficacy assessment and improve clinical trials for advanced NSCLC. The study pooled data from 984 patients with advanced NSCLC who participated in three randomized trials of platinum-based chemotherapy regimens.
A study found that patients with advanced liver, gallbladder, and bile duct cancers who developed a skin rash while treated with lapatinib lived for an average of 10 months, compared to five months for those without the rash. The treatment was well-tolerated, with two patients experiencing partial responses to treatment.
The study found that black patients had a significantly lower response rate to chemotherapy treatments compared to white patients. However, they also showed less severe toxicity and longer survival rates. Genetic differences in metabolism of chemotherapy drugs may play a role in these racial differences.
A study led by Michael C. Heinrich, M.D., found that patients with gastrointestinal stromal tumor (GIST) responded differently to Sunitinib depending on their tumor's genetic abnormality. The research highlights the importance of personalized medicine in cancer treatment.
Researchers at UC Davis Cancer Center report a significant extension of survival in advanced lung cancer patients treated with bortezomib plus standard care. The median overall survival was 11 months, with one-year survival at 46%, offering promising results for this patient population.
Researchers have found that pairing Tarceva with Celebrex significantly increases response rates in lung cancer patients, offering a potential breakthrough in treating the disease. The combination therapy has shown to increase response rates by about three-fold, with some patients experiencing responses for up to 93 weeks.
A new study suggests that an individual's unique genetic makeup can affect their risk of developing severe anemia from malaria. Researchers have identified specific genes and DNA sequences that control the production of MIF, a protein linked to malarial anemia.
Research highlights the economic burden of daycare-associated illnesses, boosts newborn immunity, identifies predictors of repeat pregnancies among teen mothers, and discusses parental consent in substance abuse research. The studies also explore growth hormone treatment for children with short stature.
A preliminary study found that combining chemotherapy with the arthritis drug etanercept increased tolerance to higher doses and reduced patient fatigue. The treatment blocks tumor necrosis factor, a substance promoting tumor growth instead of hindering it.
Deferasirox proved equally as effective as deferoxamine in reducing iron overload levels in patients with beta-thalassemia. The new drug was well-tolerated, with common side effects including skin rash and gastrointestinal issues.
Researchers at Ohio State University Comprehensive Cancer Center identified the four stages of natural killer cell maturation in secondary lymphoid tissue, such as tonsils and lymph glands. This discovery could lead to new therapies for cancer, infection, and immune deficiencies, advancing our understanding of the human immune system.
The new test measures minimal residual disease and helps identify patients who can be cured with milder treatment. It has been implemented in Brazil to treat children with lower MRD levels, reducing the risk of fatal infections.
The study found that patients receiving the combination of paclitaxel and bevacizumab had a significantly improved progression-free survival of 11.4 months, compared to 6.11 months with paclitaxel alone. This trend also suggested improved overall survival in patients treated with the new drug combination.
Dr. Olopade receives AACR-Minorities in Cancer Research-Jane Cooke Wright Lectureship for her pre-eminent research on breast cancer prevention and detection. Her work has led to strategies for identifying novel BRCA-1 mutations in African-American families.
A randomized Phase III clinical trial found decitabine improved treatment outcomes for myelodysplastic syndrome patients, achieving a 17% complete response rate. The median time to progression was also significantly longer in treated patients compared to those receiving supportive care.
A new combination therapy of melphalan, prednisone, and thalidomide has shown significant clinical benefits in elderly multiple myeloma patients. The study found higher response rates and longer event-free survival compared to the standard treatment alone, while also increasing risks of thrombosis, neurological effects, and infection.
A recent study found that elevated lactate dehydrogenase (LDH) levels can define a subgroup of sickle cell patients at risk for serious complications such as pulmonary hypertension and leg ulcerations. Patients with high LDH values had reduced survival rates compared to those with lower LDH values.
Defective apoptosis in dendritic cells can lead to autoimmune diseases such as juvenile diabetes and lupus. Research suggests that unchecked dendritic cell activity or overactivation can trigger the immune system's attack on body tissues.
Researchers found combined therapy improved survival rates for patients with AIDS-related lymphoma, comparable to non-HIV patients with lymphoma treated with CHOP. For standard-risk ARL patients, 79% achieved complete remission and 50% survived after 47 months.
A study led by Dr. Richard Goldberg found that the chemotherapy regimen FOLFOX4 is effective in treating colorectal cancer regardless of age, including older patients over 70. The analysis of nearly 4,000 patients showed consistent benefits and side effects across all age groups.
In a double-blind, placebo-controlled study, administering bone marrow stem cells to patients with acute myocardial infarction resulted in a significant reduction of the infarct size and improved regional left ventricle function. The findings suggest potential benefits for targeted clinical and pre-clinical research.
Pediatric oncologists play a crucial role in guiding patients and their families through complex treatment decisions. Effective communication is key to empowering parents to make informed choices, and clinicians must explore patient values to facilitate better decision-making.
Researchers at St. Jude Children's Research Hospital have developed an antibody therapy that successfully targets and kills cancer cells in laboratory models of neuroblastoma. The treatment, which combines antibodies with immune system cells, has shown promise for treating low initial tumor levels or small cancer cell populations.
A study found that informational campaigns alone may not be enough to increase participation in cancer clinical trials among black and Asian American patients. Lack of awareness about trial costs being covered by insurance is a significant barrier to participation, especially among those with lower incomes and education levels.
A new clinical trial found that using minimal residual disease (MRD) measurements, doctors can accurately assess treatment response and adjust therapy, leading to a high remission rate and low treatment-related mortality. This breakthrough approach improved outcomes for pediatric AML patients by identifying slow responders and intensif...
In the Phase 2 study, Aranesp demonstrated a significant erythroid response and improvements in hemoglobin levels and fatigue among low-risk MDS patients. The study found that 70% of patients with no prior erythropoietic agent use achieved an erythroid response and 67% reached target hemoglobin levels.
The International study reported a significant improvement in median time-to-disease progression with REVLIMID plus dexamethasone compared to placebo plus dexamethasone. The best response rate, complete response and near complete response rates were also higher with REVLIMID plus dexamethasone.
ASH's Minority Medical Student Award Program (MMSAP) aims to motivate minority medical students to enter the field of hematology. The program provides a research experience for students from the US and Canada, with the goal of increasing diversity in hematology.
Recent studies have shown that treatment of chronic myeloid leukemia has improved significantly, with a focus on reducing residual disease through continued therapy and new treatment options. These advances have led to better prognosis for patients, providing substantial prolongation of normal life.
Researchers found marked improvement in chronic myeloid leukemia and acute lymphocytic leukemia patients treated with AMN107. The drug, taken in pill form, outperforms Gleevec by up to 50 times in shutting down cancer-causing tyrosine kinase.
A study by Northwestern University found that a major sales promotion effort by AstraZeneca and TAP Pharmaceuticals led to significant income increases for urologists. The switch to Average Sales Price-based Medicare reimbursement is expected to decrease oncologists' revenue by 8%.
This article explores how diseases, drugs, and chemicals affected famous artists such as Michelangelo, Edvard Munch, Ivar Arosenius, and Vincent van Gogh. Clinical laboratory analysis is providing new insights into their creative achievements.